Non-small cell lung cancer
Conditions
Interventions
NSCLC patients with the ametinib regimen group:None
Sponsors
Beijing Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1.NSCLC patients with clear imaging or pathological evidence meet the indications of ametinib or the clinician determines the NSCLC patients suitable for the treatment of the above drugs according to the patient's condition. 2.Have 2 or more relevant tests required to determine the primary endpoint event; 3.Meet identifiable treatment cycles > 35d. 4.Patients who voluntarily participate and agree to sign informed consent.
Exclusion criteria
Exclusion criteria: 1.Have any serious or poorly controlled systemic disease, such as poorly controlled hypertension, active bleeding prone constitution, or active infection. 2.A history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonia requiring steroid treatment, or any evidence of clinically active interstitial lung disease. 3.Any other severe or uncontrolled symptoms that the doctor determines may increase the patient's safety risk. 4.Patients who may have poor compliance with study procedures and requirements as determined by the investigator. 5.Patients who the investigator determines have any condition that endangers patient safety or interferes with study evaluation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Safety evaluation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient's Basic Information; | — |
Countries
China
Contacts
Public ContactSun Xuelin
Beijing Hospital
Outcome results
None listed